title: Not so NICE for CML.
authors.forename: John
authors.initials: J
authors.lastname: Goldman
authors.forename: Jane
authors.initials: J
authors.lastname: Apperley
authors.forename: Richard
authors.initials: R
authors.lastname: Clark
authors.forename: Tony
authors.initials: T
authors.lastname: Green
authors.forename: Tessa
authors.initials: T
authors.lastname: Holyoake
authors.forename: Stephen
authors.initials: S
authors.lastname: O'Brien
authors.forename: Pat
authors.initials: P
authors.lastname: Shepherd
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D003561:Cytarabine / Q000627:therapeutic use; D017277:Drug Approval; D006801:Humans; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D003561:Cytarabine; D000068877:Imatinib Mesylate